Immunosuppressant Market to Reach $42.51 Bn, Globally, by 2026 at 14.7% CAGR

The global immunosuppressants industry was estimated at $13.89 billion in 2018 and is expected to hit $42.51 billion by 2026, registering a CAGR of 14.7% from 2019 to 2026.

Drivers, restraints, and opportunities-

Increase in autoimmune disorders, and surge in demand for organ transplantation drive the growth of the global immunosuppressant market. On the other hand, lack of awareness toward organ transplantation impedes the growth to certain extent. However, several growth prospects in emerging economies have created a number of opportunities for the key players in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6288

The calcineurin inhibitors segment to retain its dominance by 2026-

Based on drug class, the calcineurin inhibitors segment accounted for nearly one-third of the global immunosuppressant market share in 2018, and is expected to dominate throughout the forecast period. The same segment is also anticipated to grow at the fastest CAGR of 16.2% by 2026. This is due to increased adoption of these drugs during organ transplantation. It's also helpful in treating autoimmune disorders.

The autoimmune disorders segment to maintain the lion's share during the study period-

Based on indication, the autoimmune disorders segment contributed to nearly half of the global immunosuppressant market revenue in 2018, and is anticipated to rule the roost during 2019-2026. Rise in prevalence of autoimmune disorders such as arthritis across the globe has boosted the growth of the segment. The organ transplantation segment, on the other hand, would showcase the fastest CAGR of 15.5% till 2026. Surge in use of these drugs during organ transplantation has propelled the growth of the segment.

North America held the major share in 2018-

Based on geography, North America held the highest share in 2018, generating more than two-fifths of the global immunosuppressant market. This is attributed to increase in incidence of auto-immune disorders in this province. Simultaneously, the region across LAMEA would cite the fastest CAGR of 16.7% during the estimated period. Rise in healthcare expenditure, surge in disposable incomes, and government measures toward making immunosuppressant drugs available for patients contribute to the market growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6288

Key market players-

Bristol Myers Squibb
Pfizer
GlaxoSmithKline Plc.
Sanofi S.A.
Astellas Pharma, Inc.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Mylan Laboratories Inc.
F. Hoffmann La Roche Ltd.
Novartis AG, Inc.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Life Science Market: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.